 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Kezar Life Sciences, Inc. Nasdaq: KZR, a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported results from the completed Phase 1b dose escalation portion of its MISSION study, evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in systemic lupus erythematosus SLE patients with and without nephritis. The data are being presented b 